<DOC>
	<DOC>NCT00833781</DOC>
	<brief_summary>The purpose of the study is to find out whether an experimental autologous dendritic cell vaccine is safe, well tolerated, and whether it can strengthen the immune system's response to HIV.</brief_summary>
	<brief_title>A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects</brief_title>
	<detailed_description>This is a randomized trial to evaluate whether mRNA-transfected dendritic cell vaccination is safe and immunogenic in HIV-infected participants who are on antiretroviral therapy.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>HIV1 positive CD4+ T Cell count &gt;200 Undetectable HIV viral load for 6 months prior to screening On antiretroviral treatment for 12 months prior to screening Hepatitis C positive Detectable HIV viral load within 6 months prior to study entry Females who are pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HIV vaccine</keyword>
	<keyword>Dendritic cells</keyword>
	<keyword>treatment experienced</keyword>
</DOC>